Pharmacoeconomic aspects of poor adherence: Can better adherence reduce healthcare costs?

Journal of Medical Economics

Volumn 14, Issue 5, 2011, Pages 594-608

  Golay, Alain ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Adherence cost; Adherence intervention; Adherence monitoring; Medication adherence; Pharmacoeconomics

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ASTHMA; CARDIOVASCULAR DISEASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEVICE; DIABETES MELLITUS; GROWTH HORMONE DEFICIENCY; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HUMAN; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PATIENT MONITORING; PATIENT PREFERENCE; PHENYLKETONURIA; REVIEW; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

ECONOMICS, PHARMACEUTICAL; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MEDICATION ADHERENCE;

EID: 80052745069     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.597808     Document Type: Review

References (92)

1. World Health Organization. Adherence to long-term therapies: Evidence for action. Geneva: World Health Organization, 2003
2. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: Terminology and definitions. Value Health 2008;11:44-7
3. Aronson JK. Editors' view: Compliance, concordance, adherence. Br J Clin Pharmacol 2007;63:383-4
4. Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008(2):CD000011
5. Heisler M, Faul JD, Hayward RA, et al. Mechanisms for racial and ethnic disparities in glycemic control in middle-aged and older Americans in the health and retirement study. Arch Intern Med 2007;167:1853-60
6. Schectman JM, Nadkarni MM, Voss JD. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care 2002;25:1015-21
7. Rhee MK, Slocum W, Ziemer DC, et al. Patient adherence improves glycemic control. Diabetes Educ 2005;31:240-50
8. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000;321:405-12
9. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995;44:968-83
10. retinopathy in the diabetes control and complications trial. Diabetes 1995;44:968-83
11. Beckles GL, Engelgau MM, Narayan KM, et al. Population-based assessment of the level of care among adults with diabetes in the U.S. Diabetes Care 1998;21:1432-8
12. Diabetes and impaired glucose tolerance. In: Sicree R, Shaw J, Zimmet P (eds) IDF Diabetes Atlas, 4th Edn. 2009. Available at: Http://www.diabetesatlas. org/content/background-papers-pdf [Last accessed 31 March 2011]
13. Cramer JA, Benedict A, Muszbek N, et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: A review. Int J Clin Pract 2008;62:76-87
14. Yang Y, Thumula V, Pace PF, et al. Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: A retrospective cohort study. Clin Ther 2009;31:2178-88
15. Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009;15:728-40
16. Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract 2011;65:314-22
17. Shetty S, Secnik K, Oglesby A. Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes. J Manag Care Pharm 2005;11:559-64
18. Berger J. Economic and clinical impact of innovative pharmacy benefit designs in the management of diabetes pharmacotherapy. Am J Manag Care 2007;13(Suppl 2):S55-8
19. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-30
20. Freedberg KA, Hirschhorn LR, Schackman BR, et al. Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients. J Acquir Immune Defic Syndr 2006;43(Suppl 1):S113-18
21. Norgren S. Adherence remains a challenge for patients receiving growth hormone therapy. Pediatr Endocrinol Rev 2009;6(Suppl 4):545-8
22. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487-97
23. Electronic monitoring of adherence. AARDEX. Sion, Switzerland. Available at: Http://www.aardexgroup.com/aardex-index.php?group=aardex&id=83 [Last accessed 31 March 2011]
24. Peer reviewed publications. AARDEX. Sion, Switzerland. Available at: Http://www.iadherence.org/publication.action [Last accessed 31 March 2011]
25. Smartinhalers. Nexus6. Franklin, OH, USA. Available at: Http://www.smartinhaler.com/Researcher-SI.aspx [Last accessed 31 March 2011]
26. What is the Doser? Meditrack. Easton, MA, USA. Available at: Http://www.doser.com/dWhat.html [Last accessed 31 March 2011]
27. Dahlgren J, Veimo D, Johansson L, et al. Patient acceptance of a novel electronic auto-injector device to administer recombinant human growth hormone: Results from an open-label, user survey of everyday use. Curr Med Res Opin 2007;23:1649-55
28. Devonshire V, Arbizu T, Borre B, et al. Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: An international, single-arm, multicentre, Phase IIIb study. BMC Neurology 2010;10:28
29. Hanaire H, Lassman-Vague V, Jeandidier N, et al. Treatment of diabetes mellitus using an external insulin pump: The state of the art. Diab Metab 2008;34:401-23
30. Product information. Medtronic. Northridge, CA, USA. Available at: Http://www.minimed.com/products/index.html [Last accessed 31 March 2011]
31. DANA Diabecare R. SOOIL. Seoul, Korea. Available at: Http://www.sooil. com/NEW/eng/m3-r-01.html [Last accessed 31 March 2011]
32. Accu-Chek Combo System. Roche. Basel, Switzerland. Available at: Http://www.accu-chek.co.uk/gb/products/insulinpumps/combo.html [Last accessed 31 March 2011]
33. See how we match up to competition. Animas. West Chester, PA, USA. Available at: Http://www.animas.com/animas-insulin-pumps/onetouch-ping [Last accessed 31 March 2011]
34. Omnipod system overview. Insulet. Bedford, MA, USA. Available at: Http://www.myomnipod.com/about-omnipod/system-overview/[Last accessed March 2011]
35. George J, Kong DC, Stewart K. Adherence to disease management programs in patients with COPD. Int J Chron Obstruct Pulmon Dis 2007;2: 253-62
36. Jentzsch NS, Camargos PA, Colosimo EA, et al. Monitoring adherence to beclomethasone in asthmatic children and adolescents through four different methods. Allergy 2009;64:1458-62
37. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218-24
38. Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med 2008;10:225
39. Patti F. Optimizing the benefit of multiple sclerosis therapy: The importance of treatment adherence. Patient Prefer Adherence 2010;4:1-9
40. Haverkamp F, Johansson L, Dumas H, et al. Observations of nonadherence to recombinant human growth hormone therapy in clinical practice. Clin Ther 2008;30:307-16
41. Cazzoletti L, Marcon A, Janson C, et al. Asthma control in Europe: A real-world evaluation based on an international population-based study. J Allergy Clin Immunol 2007;120:1360-7
42. Ware NC, Idoko J, Kaaya S, et al. Explaining adherence success in sub- Saharan Africa: An ethnographic study. PLoS Med 2009;6:e11
43. Vanelli M, Pedan A, Liu N, et al. The role of patient inexperience in medication discontinuation: A retrospective analysis of medication nonpersistence in seven chronic illnesses. Clin Ther 2009;31:2628-52
44. Schectman JM, Schorling JB, Voss JD. Appointment adherence and disparities in outcomes among patients with diabetes. J Gen Intern Med 2008; 23:1685-7
45. Gold DT, McClung B. Approaches to patient education: Emphasizing the long-term value of compliance and persistence. Am J Med 2006;119 (4 Suppl 1):S32-7
46. Delamater AM. Improving patient adherence. Clinical Diabetes 2006:24;71-7
47. Saini SD, Schoenfeld P, Kaulback K, et al. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009; 15:e22-e33
48. Gregg JA, Callaghan GM, Hayes SC, et al. Improving diabetes self-management through acceptance, mindfulness, and values: A randomized controlled trial. J Consult Clin Psychol 2007;75:336-43
49. Clatworthy J, Price D, Ryan D, et al. The value of self-report assessment of adherence, rhinitis and smoking in relation to asthma control. Prim Care Respir J 2009;18:300-5
50. Bozek A, Jarzab J. Adherence to asthma therapy in elderly patients. J Asthma 2010;47:162-5
51. Chapman RH, Ferrufino CP, Kowal SL, et al. The cost and effectiveness of adherence-improving interventions for antihypertensive and lipid-lowering drugs. Int J Clin Pract 2010;64:169-81
52. Mohr DC, Boudewyn AC, Likosky W, et al. Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med 2001;23:125-32
53. Gaziano TA. Reducing the growing burden of cardiovascular disease in the developing world. Health Aff (Millwood) 2007;26:13-24
54. Bhat VG, Ramburuth M, Singh M, et al. Factors associated with poor adherence to anti-retroviral therapy in patients attending a rural health centre in South Africa. Eur J Clin Microbiol Infect Dis 2010;29:947-53
55. Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet 2010; 376:1417-27
56. National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement: Phenylketonuria: Screening and management, October 16-18, 2000. Pediatrics 2000;108:972-82
57. Management of PKU. April 2004. The National Society for Phenylketonuria (United Kingdom) Limited. Available at: Http://www.nspku.org/Documents/ Management%20of%20PKU.pdf [Last accessed 31 March 2011]
58. Ris MD, Williams SE, Hunt MM, et al. Early-treated phenylketonuria: Adult neuropsychologic outcome. J Pediatr 1994;124:388-92
59. Charman WN, Porter CJH, Mithani S, et al. Physicochemical and physiological mechanisms for the effects of food on drug absorption: The role of lipids and pH. J Pharmaceut Sci 1997;86(3):269-82
60. Yuen KCJ, Amin R. Developments in administration of growth hormone treatment: Focus on Norditropin Flexpro. Patient Pref Adhere 2011;5: 117-24
61. Ziance R, Chandler C, Bishara RH. Integration of temperature-controlled requirement into pharmacy practice. J Am Pharm Assoc 2009;49:e61-e69
62. Morgan M. The doctor-patient relationship. In: Sociology as Applied to Medicine, 6th Edn. WB Saunders Company Limited, Philadelphia, USA, 2008
63. Global Parkinson's Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson's disease: Results from an international survey. Mov Disord 2002;17:60-7
64. Arbuthnott A, Sharpe D. The effect of physician-patient collaboration on patient adherence in non-psychiatric medicine. Patient Educ Couns 2009;77:60-7
65. Kulkarni AS, Balkrishnan R, Anderson RT, et al. Medication adherence and associated outcomes in Medicare health maintenance organization-enrolled older adults with Parkinson's disease. Mov Disord 2008;23:359-65
66. Wills CJ, Scott A, Swift PG, et al. Retrospective review of care and outcomes in young adults with type 1 diabetes. BMJ 2003;327:260-1
67. Aubert RE, Herman WH, Waters J, et al. Nurse case management to improve glycemic control in diabetic patients in a health maintenance organization: A randomized, controlled trial. Ann Intern Med 1998;129:605-12
68. Raynor DK, Nicolson M, Nunney J, et al. The development and evaluation of an extended adherence support programme by community pharmacists for elderly patients at home. Int J Pharmacy Pract 2000;8:157-64
69. Blenkinsopp A, Phelan M, Bourne J, Dakhil N. Extended adherence support by community pharmacists for patients with hypertension: A randomised controlled trial. Int J Pharmacy Pract 2000;8:165-75
70. Hirsch JD, Gonzales M, Rosenquist A, et al. Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV/AIDS. J Manag Care Pharm 2011;17:213-23
71. Rosenquist A, Best BM, Miller TA, et al. Medication therapy management services in community pharmacy: A pilot programme in HIV specialty pharmacies. J Eval Clin Pract 2010;16:1142-6
72. Chernew ME, Shah MR, Wegh A, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Affairs 2008;27:103-12
73. Alikhan A, Sockolov M, Brodell RT, et al. Drug samples in dermatology: Special considerations and recommendations for the future. J Am Acad Dermatol 2010;62:1053-61
74. Johri M, David Paltiel A, Goldie SJ, et al. State AIDS Drug Assistance Programs: Equity and efficiency in an era of rapidly changing treatment standards. Med Care 2002;40:429-41
75. Walensky RP, Paltiel AD, Freedberg KA. AIDS Drug Assistance Programs: Highlighting inequities in human immunodeficiency virus-infection health care in the United States. Clin Infect Dis 2002;35:606-10
76. Morgan TM. The economic impact of wasted prescription medication in an outpatient population of older adults. J Fam Pract 2001;50:779-81
77. Peyrot M, Rubin RR, Lauritzen T, et al. Psychosocial problems and barriers to improved diabetes management: Results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study. Diabet Med 2005;22:1379-85
78. Lugaresi A. Addressing the need for increased adherence to multiple sclerosis therapy: Can delivery technology enhance patient motivation? Expert Opin Drug Deliv 2009;6:995-1002
79. Dumas H, Panayiotopoulos P, Parker D, et al. Understanding and meeting the needs of those using growth hormone injection devices. BMC Endocr Disord 2006;6:5
80. Main KM, Jørgensen JT, Hertel NT, et al. Automatic needle insertion diminishes pain during growth hormone injection. Acta Paediatr 1995; 84:331-4
81. Chatelain P, Latour S, Maetzel A. The economic value of the easypod-electronic auto injector in improving the response to growth hormone (GH) in children with idiopathic growth hormone deficiency (IGHD): A cost-consequence analysis. Poster presentation at ISPOR 13th European Congress, 6-9 November 2010, Prague, Czech Republic. Abstract available at: Http://www.ispor.org/RESEARCH-STUDY-DIGEST/details.asp [Last accessed 1 April 2011]
82. Ruger JP, Weinstein MC, Hammond SK, et al. Cost-effectiveness of motivational interviewing for smoking cessation and relapse prevention among low-income pregnant women: A randomized controlled trial. Value Health 2008;11:191-8
83. Gordon L, Graves N, Hawkes A, et al. A review of the cost-effectiveness of face-to-face behavioural interventions for smoking, physical activity, diet and alcohol. Chronic Illn 2007;3:101-29
84. Chesney A. The elusive gold standard. Future perspectives for HIV adherence assessment and intervention. J Acquir Immune Defic Syndr 2006; 43(Suppl 1):S149-55
85. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 10, 2011; 1-166. Available at: Http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [Last accessed 31 March 2011]
86. Altice FL, Maru DS, Bruce RD, et al. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: A prospective, randomized, controlled trial. Clin Infect Dis 2007;45:770-8
87. Goggin K, Liston RJ, Mitty JA. Modified directly observed therapy for antiretroviral therapy: A primer from the field. Public Health Reports 2007; 122:472-81
88. Lord J, Thomason MJ, Littlejohns P, et al. Secondary analysis of economic data: A review of cost-benefit studies of neonatal screening for phenylketonuria. J Epidemiol Community Health 1999;53:179-86
89. Santos LL, Magalhães MC, Januário JN, et al. The time has come: A new scene for PKU treatment. Genet Mol Res 2006;5:33-44
90. Blau N, Bélanger-Quintana A, Demirkol M, et al. Management of phenylketonuria in Europe: Survey results from 19 countries. Mol Genet Metab 2010;99:109-15
91. Somaraju UR, Merrin M. Sapropterin dihydrochloride for phenylketonuria. Cochrane Database Syst Rev 2010;6:CD008005
92. Tarlov AR, Ware Jr JE, Greenfield S, et al. The medical outcomes study. An application of methods for monitoring the results of medical care. J Am Med Assoc 1989;262:925-30